

Device helps doctors select lungs for transplant

April 29 2019

(HealthDay)—The Xvivo Perfusion System has been approved by the U.S. Food and Drug Administration to help doctors determine whether lungs are suitable for transplant, the agency said in a news release.

The device can temporarily ventilate, oxygenate and pump preservation solution through the lungs, allowing a transplant team to conduct a more thorough assessment of [lung](#) function.

The device was given limited approval in 2014, curtailing its use to a maximum of 8,000 patients per year, the agency said. The new approval removes that and other restrictions.

Lung transplant remains the only approved treatment for advanced lung disease, and many people die while waiting for donor lungs to become available. On average, 15 percent of donor lungs are suitable for transplant, the FDA said. About 2,530 lung transplants were performed last year, U.S. government statistics show.

The device's most common adverse reactions included bronchial complications, [respiratory failure](#) and infections.

The product is produced by the Swedish company Xvivo Perfusion Inc.

More information: The FDA has more about [this approval](#).

Copyright © 2019 [HealthDay](#). All rights reserved.

Citation: Device helps doctors select lungs for transplant (2019, April 29) retrieved 2 May 2024 from <https://medicalxpress.com/news/2019-04-device-doctors-lungs-transplant.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.